NVLN - Novelion Therapeutics Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
3.41
-0.22 (-6.06%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close3.63
Open3.62
Bid3.12 x 1200
Ask4.52 x 800
Day's Range3.38 - 3.69
52 Week Range3.08 - 10.68
Volume1,660,389
Avg. Volume71,377
Market Cap63.784M
Beta1.71
PE Ratio (TTM)N/A
EPS (TTM)-6.89
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2013-06-28
1y Target Est6.25
Trade prices are not sourced from all markets
  • Should You Invest In The Healthcare Sector And Novelion Therapeutics Inc (NASDAQ:NVLN)?
    Simply Wall St.16 days ago

    Should You Invest In The Healthcare Sector And Novelion Therapeutics Inc (NASDAQ:NVLN)?

    Novelion Therapeutics Inc (NASDAQ:NVLN), a US$76.13M small-cap, is a healthcare company operating in an industry, which faces key trends such as rising demand fuelled by an aging population and theRead More...

  • GlobeNewswire23 days ago

    MYALEPTA® (metreleptin) Receives Positive CHMP Opinion in Patients with Generalized and Partial Lipodystrophy

    Novelion Therapeutics Inc. (NVLN.TO), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced that the European Medicines Agency`s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the granting of marketing authorization, under exceptional circumstances, for MYALEPTA.

  • GlobeNewswire23 days ago

    MYALEPTA® (metreleptin) Receives Positive CHMP Opinion in Patients with Generalized and Partial Lipodystrophy

    Novelion Therapeutics Inc. (NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the granting of marketing authorization, under exceptional circumstances, for MYALEPTA.

  • Analysts Expect Breakeven For Novelion Therapeutics Inc (NASDAQ:NVLN)
    Simply Wall St.last month

    Analysts Expect Breakeven For Novelion Therapeutics Inc (NASDAQ:NVLN)

    Novelion Therapeutics Inc’s (NASDAQ:NVLN): Novelion Therapeutics Inc., a biopharmaceutical company, develops a portfolio of therapies for individuals living with rare diseases in the United States, Brazil, and internationally. With theRead More...

  • Reuterslast month

    Former Aegerion sales rep charged with defrauding U.S. insurers

    A former Aegerion Pharmaceuticals Inc sales representative was arrested Tuesday on charges that he defrauded insurance companies into paying for the company's expensive cholesterol drug. Mark Moffett was charged with wire fraud and conspiracy in a criminal complaint unsealed in Massachusetts federal court. "Mark is an innocent man," Kenneth Cunniff, Moffett's lawyer, said in an email.

  • Associated Presslast month

    Novelion Therapeutics: 1Q Earnings Snapshot

    On a per-share basis, the Vancouver, British Columbia-based company said it had a loss of $1.76. Losses, adjusted for non-recurring costs and stock option expense, came to 72 cents per share. The retinal ...

  • GlobeNewswirelast month

    Novelion Therapeutics Reports First Quarter 2018 Financial Results

    VANCOUVER, B.C., May 10, 2018-- Novelion Therapeutics Inc., a biopharmaceutical company dedicated to developing and commercializing therapies for individuals living with rare diseases, today reported financial ...

  • Novelion Therapeutics Inc (NASDAQ:NVLN): What Can We Expect From This High Growth Stock?
    Simply Wall St.2 months ago

    Novelion Therapeutics Inc (NASDAQ:NVLN): What Can We Expect From This High Growth Stock?

    In December 2017, Novelion Therapeutics Inc (NASDAQ:NVLN) announced its most recent earnings update, which suggested that losses became smaller relative to the prrior year’s level – great news for investorsRead More...

  • Does Novelion Therapeutics Inc’s (NASDAQ:NVLN) -139.66% Earnings Drop Reflect A Longer Term Trend?
    Simply Wall St.3 months ago

    Does Novelion Therapeutics Inc’s (NASDAQ:NVLN) -139.66% Earnings Drop Reflect A Longer Term Trend?

    Measuring Novelion Therapeutics Inc’s (NASDAQ:NVLN) track record of past performance is a useful exercise for investors. It enables us to understand whether or not the company has met or exceedRead More...

  • GlobeNewswire3 months ago

    Novelion Therapeutics Supports World Lipodystrophy Day

    VANCOUVER, British Columbia, March 31, 2018 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living ...

  • GlobeNewswire3 months ago

    Novelion Therapeutics Supports World Lipodystrophy Day

    VANCOUVER, British Columbia, March 31, 2018-- Novelion Therapeutics Inc., a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today recognizes ...

  • Associated Press3 months ago

    Novelion Therapeutics reports 4Q loss

    On a per-share basis, the Vancouver, British Columbia-based company said it had a loss of $1.32. Losses, adjusted for non-recurring costs and stock option expense, came to 18 cents per share. The retinal ...

  • American City Business Journals4 months ago

    Doctor pleads guilty as part of Aegerion drug misbranding probe

    A pediatric cardiologist from Georgia has pleaded guilty to divulging information about his patients to Aegerion Pharmaceuticals in 2013, as the Cambridge-based company was looking for ways to boost sales of cholesterol drug Juxtapid by promoting it for off-label uses. During a hearing on Wednesday in Boston federal court, Eduardo Montaña pleaded guilty to violating the Health Insurance Portability and Accountability Act, or HIPAA. According to a court filing, Montaña admitted that he provided an Aegerion sales representative with a list of 280 young patients under his care who could potentially receive the drug.

  • Reuters4 months ago

    Doctor admits disclosing patient info to drugmaker Aegerion

    A Georgia pediatric cardiologist pleaded guilty on Wednesday to wrongfully disclosing information about his young patients to an Aegerion Pharmaceuticals Inc sales representative seeking to identify potential new users of an expensive cholesterol drug. Dr. Eduardo Montana, 55, entered his plea in federal court in Boston after Aegerion, a unit of Novelion Therapeutics Inc , agreed in September to pay $40.1 million to resolve U.S. investigations related to its marketing of the drug, Juxtapid.

  • GlobeNewswire4 months ago

    Novelion Therapeutics Observes Rare Disease Day

    Company Joins NORD, EURORDIS, CORD, The Global Genes Project and Others Worldwide in Supporting Awareness of Rare Diseases VANCOUVER, British Columbia, Feb. 28, 2018 (GLOBE NEWSWIRE) --  Novelion Therapeutics ...

  • Reuters5 months ago

    U.S. judge sentences Novelion's Aegerion in drug marketing case

    A federal judge on Tuesday sentenced Aegerion Pharmaceuticals Inc for improperly marketing a cholesterol drug and ordered that some of the $40.1 million it agreed to pay to resolve a U.S. investigation go to the company's victims. U.S. District Judge William Young in Boston had in November rejected an initial plea deal between the U.S. Justice Department and the Novelion Therapeutics Inc unit, saying it restricted his ability to impose a sentence. The judge sentenced Aegerion under a new deal that gave him discretion to determine how much it should pay.

  • Reuters5 months ago

    Novelion's Aegerion faces sentencing in U.S. drug marketing case

    U.S. District Judge William Young of Boston said in November that the original plea deal essentially restricted him to impose only the sentence agreed to by the U.S. Justice Department and Aegerion, a unit of Novelion Therapeutics Inc. Young said the earlier plea deal reflected the "shocking disparity between the treatment of corporations and individuals in our criminal justice system." He noted people typically go before judges with wide discretion to impose a sentence. Prosecutors said after Aegerion in 2012 received U.S. Food and Drug Administration approval to market Juxtapid for treating high cholesterol in people with a rare genetic disease, the company promoted the expensive drug for patients who lacked the condition.

  • How Should You Think About Novelion Therapeutics Inc’s (NASDAQ:NVLN) Risks?
    Simply Wall St.5 months ago

    How Should You Think About Novelion Therapeutics Inc’s (NASDAQ:NVLN) Risks?

    If you are a shareholder in Novelion Therapeutics Inc’s (NASDAQ:NVLN), or are thinking about investing in the company, knowing how it contributes to the risk and reward profile of yourRead More...

  • American City Business Journals6 months ago

    Aegerion says judge’s rejection of $40M plea clouds future

    Cambridge-based Aegerion Pharmaceuticals said Thursday that a federal judge’s decision to reject its $40 million plea deal in a drug misbranding case has thrown the company into financial turmoil. In a court filing, lawyers for Aegerion asked the judge to quickly approve a new deal that the company plans to formally submit by Jan. 5. The previous agreement , under which Aegerion was to plead guilty to two misdemeanors, was rejected in November after the judge complained that it did not give him discretion to impose a sentence.

  • Reuters6 months ago

    Novelion unit asks U.S. judge to approve plea deal, cites money woes

    Aegerion Pharmaceuticals Inc has asked a U.S. judge to quickly approve a new plea agreement aimed at resolving probes into its promotion of a cholesterol drug, saying its parent company has been blocked from capital markets due to the case's uncertainty. The Novelion Therapeutics Inc unit asked U.S. District Judge William Young in Boston on Thursday to schedule a hearing so it can plead guilty to any new deal aimed at overcoming his objections to an earlier one. The initial deal in September called for Aegerion to plead guilty to two misdemeanor drug violations involving misbranding under the Food, Drug and Cosmetic Act and pay $40.1 million to resolve U.S. investigations.